MicroRNAs challenge the status quo of therapeutic targeting

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations

Abstract

MicroRNAs (miRNAs) are recently discovered posttranscriptional regulators of gene expression that have become a cause célèbre. There are currently more than 600 miRNAs identified in humans that are estimated to regulate about one third of all messenger RNA (mRNA). Because miRNA levels were found widely deregulated in diseases, they have been implicated in the underlying pathogenesis. In addition, the changes in their expression patterns are proving to be reliable diagnostic and prognostic measures. But the specific mRNA targets and, hence, function of each miRNA is still work-in-progress. This information would be necessary before fully exploiting miRNA for therapeutic purposes. In this review we will discuss why miRNAs are considered major posttranscriptional regulators and how they impact gene expression and cell function during cardiac hypertrophy and failure. In addition, we will highlight their potential for therapeutic targeting.

Original languageEnglish (US)
Pages (from-to)100-107
Number of pages8
JournalJournal of Cardiovascular Translational Research
Volume2
Issue number1
DOIs
StatePublished - Mar 2009

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Genetics
  • Pharmaceutical Science
  • Cardiology and Cardiovascular Medicine
  • Genetics(clinical)

Keywords

  • MicroRNA
  • Posttranscriptional regulation
  • Therapeutic targeting
  • miR-1
  • miR-133a
  • miR-21
  • miRNA eraser

Fingerprint

Dive into the research topics of 'MicroRNAs challenge the status quo of therapeutic targeting'. Together they form a unique fingerprint.

Cite this